Fluimucil and recent clinical practice
https://doi.org/10.18093/0869-0189-2005-0-4-97-111
Abstract
Обзор формально посвящен одному из наиболее "старых" лекарственных средств – ацетилцистеину. Действительно, его клиническое применение охватывает более чем 30-летний период, в котором можно выделить несколько этапов в изучении механизмов его фармакологической активности. Особое внимание к нему было проявлено в связи с поиском антидотов при радиационном воздействии. Ацетилцистеин вошел в список жизненно необходимых лекарственных средств при радиационном поражении человека. Одним из важных этапов в исследовании его механизмов стало применение в области респираторной медицины. Так, исходно ацетилцистеин был предложен как секретолитик, регулирующий образование муцина и стимулирующий его транспорт по дыхательным путям. В последующем была открыта его способность снижать повреждение клеточных структур свободными радикалами. Дисбаланс в системе оксиданты–антиоксиданты играет ведущую патогенетическую роль при таких заболеваниях, как хроническая обструктивная болезнь легких (ХОБЛ), респираторный дистресс-синдром и некоторых других. Необходимо подчеркнуть, что ацетилцистеин с успехом применяется при инфекционных заболеваниях как верхних, так и нижних отделов дыхательных путей. Значительный прогресс был достигнут и при таких прогностически неблагоприятных заболеваниях, какими является разнообразная группа интерстициальных заболеваний легких.
Современный этап клинического применения охватил такие области как кардиология, диабетология, химиотерапия, трансплантация органов и тканей, токсикология и некоторые другие.
Читатель найдет в обзоре С.Ю.Чикиной новую информацию, которая позволит прийти к выводу о том, что ацетилцистеин, начиная с 70-х гг. прошлого столетия, всегда остается современным лекарственным средством.
Академик РАМН профессор А.Г.Чучалин
References
1. Webb W. Clinical evaluation of a new mucolytic agent acetylcysteine. J. Thorac. Cardiovasc. Surg. 1962; 44: 330–343.
2. Reas H. The effect of N-acetylcysteine on the viscosity of tracheobronchial secretion in cystic fibrosis of the pancreas. J. Pediatr. 1963; 62: 31–35.
3. De Vries N., De Flora S. N-acetylcysteine. J. Cell Biochem. 1993; suppl. 17F: 270–278.
4. Prescott L.F., Park J., Ballantyne A. et al. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet 1977; 2: 432–434.
5. Prescott L.F., Illingworth R.N., Critchley J.A. et al. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisning. Br. Med. J. 1979; 2: 1097–1100.
6. Bonanomi L., Gazzaniga A. Toxicological, pharmacokinetic and metabolic studies of acetylcysteine. Eur. J. Respir. Dis. 1980; 61 (suppl. III): 45–51.
7. De Flora S., Izzotti A., D'Agostini F., Cesarone C.F. Antioxidant activity and other mechanisms of thiols involved in chemoprevention of mutation and cancer. Am. J. Med. 1991; 91 (3C): 122S–130S.
8. De Flora S., Cesarone C.F., Balansy R.M. et al. Chemopreventive properties and mechanisms of N-acetylcysteine. The experimental background. J. Cell Biochem. 1995; 22 (suppl.): 33–41.
9. De Flora S., Astengo M., Serra D., Bennicelli S. Inhibition of urethan-induced lung tumours in mice by dietary N-acetylcysteine. Cancer Lett. 1986; 32: 235–241.
10. Rogers D.F., Jeffery P.K. Inhibition by oral N-acetylcysteine of cigarette smoke-induced "bronchitis" in the rat. Exp. Lung Res. 1986; 10: 267–283.
11. Moldeus P., Cotgreave I.A., Berddren M. Lung protection by a thiol-containing antioxidant N-acetylcysteine. Respiration 1986; 50: 31–42.
12. De Flora S., Bennicelli C., Zanacchi P. et al. In vitro effects of N-acetylcysteine on the mutagenicity of direct-acting compounds and procarcinogens. Carcinogenesis (Lond.) 1984; 5: 505–510.
13. Hochstein P., Atallah A.S. The nature of oxidants and antioxidant systems in the inhibition of mutation and cancer. Mutat. Res. 1988; 202: 363–375.
14. Rouse B.T., Horohov D.W. Immunosuppression in viral infections. Rev. Infect. Dis. 1986; 8: 850–873.
15. Maeda H., Akaike T. Oxygen-free radicals as pathogenic molecules in viral diseases. Proc. Soc. Exp. Biol. (N.Y.) 1991; 198: 721–727.
16. De Flora S., Grassi C., Carati L. Attenuation of influenzalike symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur. Respir. J. 1997; 10: 1535–1541.
17. Peristeris P., Clark B.D., Gatti S. et al. N-acetylcysteine and glutathione as inhibitors of tumor necrosis factor production. Cell. Immunol. 1992; 140: 390–399.
18. Murray C.J.L., Lopez A.D. Evidence-based health policy — lessons from the Global Burden of Disease Study. Science 1996; 274: 740–743.
19. World Health Organization. World health report. Geneva: World Health Organization; 2000.
20. MacNee W. Oxidant / antioxidants and COPD. Chest 2000; 117: 303S–317S.
21. Kharitonov S.A., Barnes P.J. Exhaled markers of pulmonary diseases. Am. J. Respir. Crit. Care Med. 2001; 163: 1693–1722.
22. Tattersall A.B., Bridgman K.M., Huitson A. Acetylcysteine (Fabrol) in chronic bronchitis — a study in general practice. J. Intern. Med. Res. 1983; 11: 279–284.
23. Stey C., Steurer J., Bachmann S. et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur. Respir. J. 2000; 16: 253–262.
24. Watson J.H.L., Brinkman G.L. Electron microscopy of the epithelial cells of normal and bronchitic human bronchus. Am. Rev. Respir. Dis. 1964; 90 (6): 851–855.
25. Salvato G. Some histological changes in chronic bronchitis and asthma. Thorax 1968; 23: 168–172.
26. Mullen B.J., Wright J.L., Wiggs B.R. et al. Structure of central airway in current smokers and ex-smokers with and without mucus hypersecretion: relationship to lung function. Thorax 1987; 42: 843–848.
27. Riise G.C., Larsson S., Larsson P. et al. The intrabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy. Eur. Respir. J. 1994; 7: 94–101.
28. Rasmussen J.B., Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled release tablets in patients with chronic bronchitis. Eur. Respir. J. 1988; 1: 351–355.
29. Grandjean E.M., Berthet P.H., Ruffnman R., Leuenberger P.H. Cost-effectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis. Pharmacol. Res. 2000; 42 (1): 39–50.
30. Grandjean E.M., Berthet P., Ruffnman R., Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin. Ther. 2000; 22 (2): 209–221.
31. Poole P.J., Black P.N. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. Br. Med. J. 2001; 322: 1–6.
32. Gerrits C.M.J.M., Herings R.M.C., Leufkens H.G.M., Lammers J.-W.J. N-acetylcysteine reduces the risk of rehospitalizations among patients with chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 795–798.
33. Decramer M., Rutten-van Molken M., Dekhuijzen P.N. et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005; 365 (9470): 1552 — 1560.
34. Belman M.J., Batnick W.C., Shin J.W. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1996; 153: 967–975.
35. Tantucci C., Duguet A., Similowski T. et al. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur. Respir. J. 1998; 12: 799–804.
36. Duranti R., Filippelli M., Bianchi R. et al. Inspiratory capacity and decrease in lung hyperinflation with albuterol in COPD. Chest 2002; 122: 2009–2014.
37. Hansen N.C., Skriver A., Brorsen-Riis L. et al. Orally administered N-acetylcysteine may improve general wellbeing in patients with mild chronic bronchitis. Respir. Med. 1994; 88 (7): 531–535.
38. Sen C.K., Atalay M., Hanninen O. Exercise-induced oxidative stress: glutatione supplementation and deficiency. J. Appl. Physiol. 1994; 77 (5): 2177–2187.
39. Vassilakopouolos T., Karatsa M.-H., Latsaounou P. et al. Antioxidants attenuate the plasma cytokine response to exercise in humans. J. Appl. Physiol. 2003; 94: 1025–1032.
40. Reid M.B., Stokic S., Koch S.M. et al. N-acetylcysteine inhibits muscle fatigue in humans. J. Clin. Invest. 1994; 94: 2468–2474.
41. Medved I., Brown M.J., Bjorksen A.R. et al. N-acetylcysteine infusion alters blood redox status but not time to fatigue during intense exercise in humans. J. Appl. Physiol. 2003; 94: 1572–1582.
42. Medved I., Brown M.J., Bjorksten A.R., McKenna M.J. Effects if intravenous N-acetylcysteine infusion on time fatigue and potassium regulation during prolonged cycling exercise. J. Appl. Physiol. 2004; 96: 211–217.
43. Medved I., Brown M.J., Bjorksen A.R. et al. N-acetylcysteine enhances muscle cysteine and glutathione availability and attenuates fatigue during prolonged exercise in endurance-trained individuals. J. Appl. Physiol. 2004; 97: 1477–1485.
44. Travaline J.M., Sudarshan S., Roy B.G. et al. Effect of N-acetylcysteine on human diaphragm strength and fatigability. Am. J. Respir. Crit. Care Med. 1997; 156: 1567–1571.
45. Polkey M.I., Kyroussis D., Hamnegard C.H. et al. Diaphragm strength in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1996; 154: 1310–1317.
46. Gosselink R., Troosters T., Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am. J. Respir. Crit. Care Med. 1996; 153: 976–980.
47. Bernard S., LeBlanc P., Whittom F. et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 158: 629–634.
48. Couillard A., Maltais F., Saey D. et al. Exercise-induced quadriceps oxidative stress and peripheral muscle dysfunction in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003; 167: 1664–1669.
49. Koechlin C., Couillard A., Simar D. et al. Does oxidative stress alter quadriceps endurabce in chronic obstructive pulmonary disease? Am. J. Respir. Crit. Care Med. 2004; 169: 1022–1027.
50. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am. J. Respir. Crit. Care Med. 2000; 161: 646–664.
51. Hamman L., Rich A.R. Fulminating diffuse interstitial fibrosis of the lungs. Trans. Am. Clin. Climatol. Assoc. 1935; 51: 154–163.
52. Beeh K.M., Beier J., Haas I.C. et al. Glutathione deficiency of the lower respiratory tract in patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 2002; 19: 1119–1123.
53. Behr J., Degenkolb B., Krombach F., Vogelmeier C. Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine. Eur. Respir. J. 2002; 19: 906–911.
54. Meyer A., Buhl R., Magnussen H. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur. Respir. J. 1994; 7: 431–436.
55. Meyer A., Buhl R., Kampf S., Magnussen H. Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am. J. Respir. Crit. Care Med. 1995; 152 (3): 1055–1060.
56. Benr J., Maier K., Degenkolb B. et al. Antioxidant and clinical effects og high-dose N-acetylcysteine in fibrosing alveolitis. Am. J. Respir. Crit. Care Med. 1997; 156: 1897–1901.
57. Demedts M.G.P., Nicholson A.G., Verbeken E.K. et al. Ifigenia-study on N-acetylcysteine in idiopathic pulmonary fibrosis (IPF): comparison of HRCT and lung biopsy. Eur. Respir. J. 2001; 18 (suppl. 33): 527s.
58. Demedts M., Thomeer M., Verschakelen J. et al. IFIGENIA-study: methods, patient characteristics and diagnostic confirmation by independent HRCT and histology committees. Eur. Respir. J. 2002; 20 (suppl. 38): 588s.
59. Thomeer M., Demedts M., Behr J. et al. Survival in idiopathic pulmonary fibrosis: results of the IFIGENIA follow up study. Eur. Respir. J. 2004; 24 (suppl. 48): 254s.
60. Demedts M., Behr J., Buhl R. et al. IFIGENIA-study in IPF: effects of N-acetylcysteine (NAC) on CRP, dyspnea, exercise test and HRCT. Eur. Respir. J. 2004; 24 (suppl. 48): 668s.
61. Demedts M., Behr J., Buhl R. et al. IFIGENIA: effects of N-acetylcysteine (NAC) on primary end points VC and Dlco. Eur. Respir. J. 2004; 24 (suppl. 48): 668s.
62. Behr J., Demedts M., Buhl R. et al. IFIGENIA (Idiopathic pulmonary Fibrosis International Group Exploring NAC I Annual): effects of N-acetylcysteine (NAC) on lung function and gas exchange in IPF patients. Eur. Respir. J. 2004; 24 (suppl. 48): 668s.
63. National Institutes of Health (NIH) / National Heart, Lung, Blood Institute. Facts about cystic fibrosis. Bethesda, MD, U.S. Dept of Health and Human Services; 1995. NIH Publication No. 95–3650.
64. Bedrossian C.W., Greenberg S.D., Singer D.B. et al. The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups. Hum. Pathol. 1976; 7: 195–204.
65. Sheppard M.N. The pathology of cystic fibrosis. In: Hodson M.E., Geddes D.M., eds. Cystic fibrosis. London: Chapman & Hall Medical; 1997. 13–22.
66. Ratjen F., Wonne R., Posselt H.G. et al. A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. Eur. J. Pediatr. 1985; 144 (4): 374–378.
67. Stafanger G., Garne S., Howitz P. et al. The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia. Eur. Respir. J. 1988; 1 (2): 161–167.
68. Stafanger G., Koch C. N-acetylcysteine in cystic fibrosis and Pseudomonas aeruginosa infection: clinical score, spirometry and ciliary motility. Eur. Respir. J. 1989; 2: 234–237.
69. Maayan C., Bar-Yishay E., Yaacobi T. et al. Immediate effect of various treatment on lung function in infants with cystic fibrosis. Respiration 1989; 55 (3): 144–151.
70. Laurent T., Markett M., Feihi F. et al. Oxidant-antioxidant balance in granulocytes during ARDS. Effect of N-acetylcysteine. Chest 1996; 109 (1): 163–166.
71. Pepe P.E. Clinical entity of adult respiratory distress syndrome: definition. prediction, and prognosis. Crit. Care Clin. 1986; 2: 377–403.
72. Repine J.E., Parsons P.E. Oxidant-antioxidant balance in endotoxin-induced oxidative injury and tolerance to oxidative injury. In: Brigham K.L., ed. Endotoxin and the lung. New York: Marcel Dekker; 1994. 207–227.
73. Bernard G.R., Lucht W.D., Niedermeyer M.E. et al. Effect of N-acetylcysteine on the pulmonary response to endotoxin in the awake sheep and upon in vitro granulocyte function. J. Clin. Invest. 1984; 73: 1772–1784.
74. Jepsen S., Herlevsen P., Knudsen P. et al. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: a prospective, randomized, placebo-controlled study. Crit. Care Med. 1992; 20 (7): 918–923.
75. Suter P.M., Domenighetti G., Schaller M.D. et al. N-acetylcysteine enhances recovery from acute lung injury in man. A randomized, double-blind, placebo-controlled clinical study. Chest 1994; 105: 190–194.
76. Spies C.D., Reinhart K., Witt I. et al. Influence of N-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients: results from a prospective, randomized, double-blind study. Crit. Care Med. 1994; 22 (11): 1738–1746.
77. Domenighetti G., Suter P.M., Schaller M.D. et al. Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study. J. Crit. Care 1997; 12 (4): 177–182.
78. Del Sorbo L., Zhang H. Is there a place for N-acetylcysteine in the treatment of septic shock? Crit. Care 2004; 8 (2): 93–95.
79. Bergstrand H., Bjornson A., Eklung A. et al. Stimuliinduced superoxide radical generation in vitro by human alveolar macrophages from smokers: modulation by N-acetylcysteine treatment in vitro. J. Free Radic. Biol. Med. 1986; 2: 119–127.
80. Linden M., Wieslander E., Eklund A. et al. Effects of oral N-acetylcysteine on cell content and macrophage function in bronchoalveolar lavage from healthy smokers. Eur. Respir. J. 1988; 1: 645–650.
81. Eklund A., Erikkson O., Hakansson L. et al. Oral N-acetylcysteine reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variables. Eur. Respir. J. 1988; 1: 832–838.
82. Schooten F.J.V., Nia A.B., De Flora S. et al. Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers. Cancer Epidemiol., Biomarkers Prev. 2002; 11: 167–175.
83. van Zandwijk N., Dalesio O., Pastorino U. et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. J. Nat. Cancer Inst. 2000; 92 (120): 977–986.
84. Potter J.D., Bigler J., Fosdick L. et al. Colorectal adenomatous and hyperplastic polyps: smoking and N-acetyltransferase 2 polymorphisms. Cancer Epidemiol. Biomarkers Prev. 1999; 8: 69–75.
85. Heineman E.F., Zham S.H., McLaughlin J.K., Vaught J.B. Increased risk of colorectal cancer among smokers: results of a 26-year follow-up of US veterans and a review. Int. J. Cancer 1994; 59: 728–738.
86. Greenwald P., Kelloff G.J., Boone C.W., McDonald S.S. Genetic and cellular changes in colorectal cancer: proposed targets of chemopreventive agents. Cancer Epidemiol. Biomarkers Prev. 1995; 4: 691–702.
87. Ponz de Leon M., Roncucci L. Chemoprevention of colorectal tumors: role of lactulose and of other agents. Scand. J. Gastroenterol. 1997; 222: 72–75.
88. Estensen R.D., Levy M., Klopp S.J. et al. N-acetylcysteine suppression of the proliferative index in the colon of patients with previous adenomatous colonic polyps. Cancer Lett. 1999; 147: 109–114.
89. Fishbane S., Durham J.H., Marzo K., Rudnick M. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy. J. Am. Soc. Nephrol. 2004; 15: 251–260.
90. Zager R.A., Johnson A.C., Hanson S.Y. Radiographic contrast media-induced tubular injury: evaluation of oxidant stress and plasma membrane integrity. Kidney Int. 2003; 64: 128–139.
91. Tepel M., van der Giet M., Schwarzfeld C. et al. Prevention of radiographic-contrast-agent-induced reductrions in renal function by acetylcysteine. N. Engl. J. Med. 2000; 343 (3): 180–184.
92. Durham J.D., Caputo C., Dokko J. et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002; 62: 2202–2207.
93. Weisberg I.S., Kurnik P.B., Kurnik B.R. Risk of radiocontrast nephropathy in patiehts with and without diabetes mellitus. Kidney Int. 1994; 45 (1): 259–265.
94. Kay J., Chow W.H., Chan T.M. et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiographt and intervention: a randomized controlled trial. J.A.M.A. 2003; 289: 553–558.
95. Shyu K.G., Cheng J.J., Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J. Am. Coll. Cardiol. 2002; 40: 1383–1388.
96. Diaz-Sandonal L.J., Kosowsky B.D., Losordo D.W. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am. J. Cardiol. 2002; 89: 356–358.
97. Baker C.S., Wragg A., Kumar S. et al. A rapid protocol for the prevention of contrast-induced renal dysfunction: The RAPPID study. J. Am. Coll. Cardiol. 2003; 41: 2114–2118.
98. Allaqaband S., Tumuluri R., Malik A.M. et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radio contrast-induced nephropathy. Catheter. Cardiovasc. Interv. 2002; 57: 279–283.
99. Boccaladnro F., Amhad M., Smalling P.W., Sdringola S. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter. Cardiovasc. Interv. 2003; 58: 336–341.
100. Briguori C., Manganelli F., Scarpato P. et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J. Am. Coll. Cardiol. 2002; 40: 298–303.
101. Goldenberg I., Jones M., Metetzki S. et al. Contrast-associated nephropathy and clinical outcome of patients with chronic renal insufficiency undergoing cardiac catheterization: lack of additive benefit of acetylcysteine to saline hydration. J. Am. Coll. Cardiol. 2003; 41: 537A.
102. Loutrianakis E., Stella D., Hussain A. et al. Randomized comparison of fenaldopam and N-acetylcysteine to saline in the prevention of radiocontrast nephropathy. J. Am. Coll. Cardiol. 2003; 41: 327A.
103. Oldemeyer J.B., Cichowski E.K., Wurdeman R.L. et al. Prophylactic acetylcysteine is not effective in preventing contrast-induced nephropathy following coronary angiography. Am. Heart J. 2003; 146: E23.
104. Vallero A., Cesano G., Pozzato M. et al. Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC). G. Ital. Nefrol. 2002; 19: 529–533.
105. Brick R., Krzossok S., Markowetz F. et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003; 362: 598–603.
106. Ignatto L. Endothelium-derived nitric oxide: pharmacology and relationship to the actions of organic esters. Pharmacol. Res. 1989; 6: 651–659.
107. Ardissino D., Merlini P.A., Savonitto S. et al. Effect of transdermal nitroglycerin or N-acetylcysteine, or both, in the long-term treatment of unstable angina pectoris. J. Am. Coll. Cardiol. 1997; 29 (5): 941–947.
108. Boesgaard S., Aldershvile J., Poulsen H.E. Preventive administration of intravenous N-acetylcysteine and development of tolerance to isosorbide dinitrate in patients with angina pectoris. Circulation 1992; 85 (1): 143–149.
109. Andrews N.P., Prasad A., Quyyumi A.A. N-acetylcysteine improves coronary and peripheral vascular function. J. Am. Coll. Cardiol. 2001; 37 (1): 117–123.
110. Horowitz J.D., Antman E.M., Lorell B.H. et al. Potentiation of cardiovascular effects of nitroglycerin by N-acetylcysteine. Circulation 1983; 68 (8): 1247–1253.
111. Parker J.O., Farrell B., Lahey K.A., Rose B.F. Nitrate tolerance: the lack of effect of N-acetylcysteine. Circulation 1987; 76 (3): 572–576.
112. Winniford M.D., Kennedy P.L., Wells P.J., Hills L.D. Potentiation of nitroglycerin-induced coronary dilatation by N-acetylcysteine. Circulation 1986; 73 (1): 138–142.
113. Sochman J., Vrbska J., Musilova B., Pocek M. Infarct size limitation: acute N-acetylcysteine defemse (ISLAND trial): preliminary analysis and report after the first 30 patients. Clin. Сardiol. 1996; 19 (2): 94–100.
114. Litovitz T.L., Klein-Schwartz W., White S. et al. 2000 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am. J. Emerg. Med. 2001; 19: 337–395.
115. Moklesi B., Leikin J.B., Murray P., Corbridge T.C. Adult toxicology in critical care. Part II: specific poisoning. Chest 2003; 123: 897–922.
116. Smilkstein M.J., Knapp G.L., Kulig K.W. et al. Efficacy of oral N-acetylcysteine in the treatment of accetaminophen overdose: analysis of the national multicenter study (1976–1985). N. Engl. J. Мed. 1988; 319: 1557–1562.
117. Harrison P.M., Keays R., Bray G.P. et al. Improves outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet 1990; 335: 1572–1573.
118. Makin A.J., Wendon J., Williams R. A 7-year experience of severe acetaminophen-induced hepatoxity (1987–1993). Gastroenterology. 1995; 109 (6): 1907–1916.
119. Kelly D.A. Managing liver failure. Postgrad. Med. J. 2002; 78: 660–667.
120. Woo O.F., Mueller P.D., Olson K.R. et al. Shorter duration of oral N-acetylcysteine therapy for acute acetaminophen overdose. Ann. Emerg. Med. 2000; 35: 363–368.
121. Wallace C.I., Dargan P.I., Jones A.L. Paracetamol poisoning: an evidence-based flowchart to guide management. Emerg. J. Med. 2002; 19: 202–205.
122. Smilkstein M.J., Bronstein A.C., Linden C. et al. Acetaminophen overdose: a 48-h intravenous N-acetylcysteine treatment protocol. Ann. Emerg. Med. 1991; 20: 1058–1063.
123. Buckley N.A., Whyte I.M., O'Connel D.L. et al. Oral or intravenous N-acetylcysteine: which is the treatment of choice for acetaminophen (paracetamol) poisoning? J. Toxicol. Clin. Toxicol. 1999; 37 (6): 759–767.
124. Weiss L., Hilst E., Hofschneider P.H. Anti-hepatitis B virus activity of N-acetylcysteine, new aspect a well established drug. Antiviral Res. 1996; 32: 43–53.
125. Bova P., de la Pena A., Beloqui O. et al. Antioxidant status and glutathione metabolism in peripheral blood mononuclear cells from patients with chronic hepatitis C. J. Hepatol. 1999; 31 (5): 808–814.
126. Larrea E., Beloqui O., Munoz-Navas M.A. et al. Superoxide dismutase in patients with chronic hepatitis C virus infection. Free Radic. Biol. Med. 1998; 24 (7–8): 1235–1241.
127. Neri S., Ierna D., Antoci S. et al. Association of alphainterferon and acetyl cysteine in patients with chronic C hepatitis. Panminerva Med. 2000 42 (3): 187–192.
128. Beloqui O., Prieto J., Suarez M. et al. N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. J. Interferon Res. 1993; 13 (4): 279–282.
129. Cimino L., Belisario M.A., Intrieri M. et al. Effect of N-acetylcysteine on lymphomonocyte glutathione and response to interferon treatment in C-virus chronic hepatitis. Ital. J. Gastroenterol. Hepatol. 1998; 30 (2): 189–193.
130. Weidenbach H., Arth M., Adler G. et al. Treatment of chronic hepatitis B with high-dose intravenous N-acetyl-L-cysteine. Hepatogastroenterology 2003; 50 (54): 2105–2108.
131. Ideo G., Bellobuono A., Tempini S. et al. Antioxidant drugs combined with alpha-interferon in chronic hepatitis C not responsive to alpha-interferon alone: a randomized, multicentre study. Eur. J. Gastroenterol. Hepatol. 1999; 11 (11): 1203–1207.
132. Gunduz H., Karabay O., Tamer A. et al. N-acetyl cysteine therapy in acute viral hepatitis. Wld J. Gastroenterol. 2003; 9 (12): 2698–2700.
133. Herzenberg L.A., De Rosa S.C., Dubs J.G. et al. Glutathione deficiency is associated with impaired survival in HIV disease. Proc. Natl. Acad. Sci. U S A 1997; 94: 1967–1972.
134. Malorni W., Rivabene R., Lucia B.M. et al. The role of oxidative imbalance in progression of AIDS: effect of the thiol supplier N-acetylcysteine. AIDS Res. Hum. Retrovirus. 1998; 14 (7): 1589–1596.
135. Droge W., Breitkreutz R. Glutathione and immune function. Proc. Nutr. Soc. 2000; 59 (4): 595–600.
136. Nakamura H., Masutani H., Yodoi J. Redox imbalance and its control in HIV infection. Antioxid. Redox Signal. 2002; 4 (3): 455–464.
137. Baruchei S., Wainberg M.A. The role of oxidative stress in disease progression in individuals infected by the human immunodeficiency virus. J. Leukocyte Biol. 1992; 52 (1): 111–114.
138. Breitkreutz R., Pittack N., Nebe C.T. et al. Improvement of immune functions in HIV infection by sulfur supplementation: two randomized trials. J. Mol. Med. 2000; 78 (1): 55–62.
139. Lopez O., Bonnefoni-Rousselot D., Edeas M. et al. Could antioxidant supplementation reduce antiretroviral therapy-induced chronic stable hyperlactatemia? Biomed and Pharmacother. 2003; 57 (3–4): 113–116.
140. De Rosa S.C., Zaretsky M.D., Dubs J.G. et al. N-acetylcysteine replenishes glutathione in HIV infection. Eur. J. Clin. Invest. 2000; 30 (10): 915–920.
141. James J.S. Stanford NAC study: glutathione level predicts survival. AIDS Treat. News 1997; 7 (266): 1–5.
Review
For citations:
Chikina S.Yu. Fluimucil and recent clinical practice. PULMONOLOGIYA. 2005;(4):97-111. (In Russ.) https://doi.org/10.18093/0869-0189-2005-0-4-97-111
Views:
1159
Email this article 